In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.

Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.

Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.

CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.

The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.

The FDA has approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatments for those with disease progression.

Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.

North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.